COMPANY PROFILE

MaxWell Biosciences

Explore full profile

Developing an entirely new class of patented, virucidal, small molecule drugs

Austin, United StatesFounded 2016Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MaxWell Biosciences

Maxwell Biosciences is a biotechnology company focused on developing next-generation virucidal drugs that irreversibly deactivate human herpes virus and pandemic pathogens. The company operates in the pharmaceutical and healthcare market, primarily serving medical institutions, research organizations, and healthcare providers. Maxwell's business model revolves around the research, development, and commercialization of small molecule drugs designed to mimic the antiviral properties of natural antimicrobial peptides. These drugs target and deactivate viral DNA, RNA, and proteins, offering a novel approach to antiviral treatment. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. Currently, Maxwell is advancing its lead candidate, MXB 005, targeting Herpes cold sores, and is in the lead generation stage for an inhaled therapeutic for SARS CoV 2. The company collaborates with large institutional partners and benefits from government-funded research to validate its drug efficacy and safety.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Austin, United States
Employees: 22
Open positions: 2
Dealroom signal: 68.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning MaxWell Biosciences.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Aug 2025	$20M	$80M	Undisclosed	↗
GRANT✓Other financing	Oct 2024	$3M	—	MTEC	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

MaxWell Biosciences website traffic

Latest recorded traffic for MaxWell Biosciences is 3.1K monthly website visits, up 121.4% over the last three months. MaxWell Biosciences's team declined 8.3% over the past year.

Latest monthly visits3.1K 3-month web change+121.4% 1-year team growth-8.3%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

InternAustin, United States · Other · Jul 23, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
1T1E TherapeuticsFocuses on developing oligonucleotide therapeutics to treat various diseases	Rehovot, Israel	Operational	49	$120M	$480M
APAtheric PharmaceuticalBiopharmaceutical company focused on the rapid development and commercialization	Troy, United States	Operational
NENeurovanceClinical stage neuroscience company	Cambridge, United States	Acquired
OTOxygen TherapyAims to help people on Jersey with various conditions such as MS, Fibromyalgia, ME, Chronic Fatigue, and many other conditions	Newton, United States	Operational
XPX4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment	Cambridge, United States	Operational
MNMIVI NeuroscienceMIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures	Eden Prairie, United States	Operational
CTCognition TherapeuticsA drug discovery and development company that helps restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders	Town of Harrison, United States	Operational
NENeumentumAnd commercializes novel non-opioid pain products	Morristown, United States	Operational